{"id":"https://openalex.org/W2264947172","doi":null,"title":"A phase I study of q3W R1507, a human monoclonal antibody IGF-1R (insulin-like growth factor receptor) antagonist in patients with advanced solid tumors","display_name":"A phase I study of q3W R1507, a human monoclonal antibody IGF-1R (insulin-like growth factor receptor) antagonist in patients with advanced solid tumors","publication_year":2007,"publication_date":"2007-11-01","ids":{"openalex":"https://openalex.org/W2264947172","mag":"2264947172"},"language":"en","primary_location":{"id":"mag:2264947172","doi":null,"is_oa":false,"landing_page_url":"http://mct.aacrjournals.org/content/6/11_Supplement/A77","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":null},"volume":null,"type":"article","indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5031165814","display_name":"Jordi Ahnert Rodon","orcid":"https://orcid.org/0000-0001-6467-3632","observed_orcids":["https://orcid.org/0000-0001-6467-3632","https://orcid.org/0000-0003-2234-5248"]},"institutions":[{"id":"https://openalex.org/I4390039325","display_name":"Rutgers Cancer Institute","ror":"https://ror.org/0060x3y55","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I102322142","https://openalex.org/I4390039302","https://openalex.org/I4390039325"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jordi Rod\u00f3n","raw_affiliation_strings":["Cancer Therapy & Research Ctr., San Antonio, TX, Cancer Institute of New Jersey, New Brunswick, NJ, Hoffman-La Roche Inc., Nutley, NJ, MD Anderson Cancer Ctr, Houston, TX"],"raw_orcid":"https://orcid.org/0000-0001-6467-3632","affiliations":[{"raw_affiliation_string":"Cancer Therapy & Research Ctr., San Antonio, TX, Cancer Institute of New Jersey, New Brunswick, NJ, Hoffman-La Roche Inc., Nutley, NJ, MD Anderson Cancer Ctr, Houston, TX","institution_ids":["https://openalex.org/I4390039325"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5070570779","display_name":"Amita Patnaik","orcid":"https://orcid.org/0000-0002-4144-2193","observed_orcids":["https://orcid.org/0000-0002-4144-2193"]},"institutions":[{"id":"https://openalex.org/I4390039325","display_name":"Rutgers Cancer Institute","ror":"https://ror.org/0060x3y55","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I102322142","https://openalex.org/I4390039302","https://openalex.org/I4390039325"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Amita Patnaik","raw_affiliation_strings":["Cancer Therapy & Research Ctr., San Antonio, TX, Cancer Institute of New Jersey, New Brunswick, NJ, Hoffman-La Roche Inc., Nutley, NJ, MD Anderson Cancer Ctr, Houston, TX"],"raw_orcid":"https://orcid.org/0000-0002-4144-2193","affiliations":[{"raw_affiliation_string":"Cancer Therapy & Research Ctr., San Antonio, TX, Cancer Institute of New Jersey, New Brunswick, NJ, Hoffman-La Roche Inc., Nutley, NJ, MD Anderson Cancer Ctr, Houston, TX","institution_ids":["https://openalex.org/I4390039325"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071773606","display_name":"Mark N. Stein","orcid":"https://orcid.org/0000-0002-0853-3640","observed_orcids":["https://orcid.org/0000-0002-0853-3640","https://orcid.org/0000-0002-2573-4911"]},"institutions":[{"id":"https://openalex.org/I4390039325","display_name":"Rutgers Cancer Institute","ror":"https://ror.org/0060x3y55","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I102322142","https://openalex.org/I4390039302","https://openalex.org/I4390039325"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mark N. Stein","raw_affiliation_strings":["Cancer Therapy & Research Ctr., San Antonio, TX, Cancer Institute of New Jersey, New Brunswick, NJ, Hoffman-La Roche Inc., Nutley, NJ, MD Anderson Cancer Ctr, Houston, TX"],"raw_orcid":"https://orcid.org/0000-0002-0853-3640","affiliations":[{"raw_affiliation_string":"Cancer Therapy & Research Ctr., San Antonio, TX, Cancer Institute of New Jersey, New Brunswick, NJ, Hoffman-La Roche Inc., Nutley, NJ, MD Anderson Cancer Ctr, Houston, TX","institution_ids":["https://openalex.org/I4390039325"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5060992997","display_name":"Anthony W. Tolcher","orcid":"https://orcid.org/0000-0002-6322-9721","observed_orcids":["https://orcid.org/0000-0002-6322-9721"]},"institutions":[{"id":"https://openalex.org/I4390039325","display_name":"Rutgers Cancer Institute","ror":"https://ror.org/0060x3y55","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I102322142","https://openalex.org/I4390039302","https://openalex.org/I4390039325"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Anthony W. Tolcher","raw_affiliation_strings":["Cancer Therapy & Research Ctr., San Antonio, TX, Cancer Institute of New Jersey, New Brunswick, NJ, Hoffman-La Roche Inc., Nutley, NJ, MD Anderson Cancer Ctr, Houston, TX"],"raw_orcid":"https://orcid.org/0000-0002-6322-9721","affiliations":[{"raw_affiliation_string":"Cancer Therapy & Research Ctr., San Antonio, TX, Cancer Institute of New Jersey, New Brunswick, NJ, Hoffman-La Roche Inc., Nutley, NJ, MD Anderson Cancer Ctr, Houston, TX","institution_ids":["https://openalex.org/I4390039325"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5000728724","display_name":"Chee M. Ng","orcid":"https://orcid.org/0000-0002-9452-7748","observed_orcids":["https://orcid.org/0000-0002-9452-7748","https://orcid.org/0000-0001-6053-9196"]},"institutions":[{"id":"https://openalex.org/I4390039325","display_name":"Rutgers Cancer Institute","ror":"https://ror.org/0060x3y55","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I102322142","https://openalex.org/I4390039302","https://openalex.org/I4390039325"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Chee M. Ng","raw_affiliation_strings":["Cancer Therapy & Research Ctr., San Antonio, TX, Cancer Institute of New Jersey, New Brunswick, NJ, Hoffman-La Roche Inc., Nutley, NJ, MD Anderson Cancer Ctr, Houston, TX"],"raw_orcid":"https://orcid.org/0000-0001-6053-9196","affiliations":[{"raw_affiliation_string":"Cancer Therapy & Research Ctr., San Antonio, TX, Cancer Institute of New Jersey, New Brunswick, NJ, Hoffman-La Roche Inc., Nutley, NJ, MD Anderson Cancer Ctr, Houston, TX","institution_ids":["https://openalex.org/I4390039325"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5023961383","display_name":"Cinara Dias","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4390039325","display_name":"Rutgers Cancer Institute","ror":"https://ror.org/0060x3y55","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I102322142","https://openalex.org/I4390039302","https://openalex.org/I4390039325"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Cinara Dias","raw_affiliation_strings":["Cancer Therapy & Research Ctr., San Antonio, TX, Cancer Institute of New Jersey, New Brunswick, NJ, Hoffman-La Roche Inc., Nutley, NJ, MD Anderson Cancer Ctr, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Therapy & Research Ctr., San Antonio, TX, Cancer Institute of New Jersey, New Brunswick, NJ, Hoffman-La Roche Inc., Nutley, NJ, MD Anderson Cancer Ctr, Houston, TX","institution_ids":["https://openalex.org/I4390039325"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5010960151","display_name":"G\u00e9rard Greig","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4390039325","display_name":"Rutgers Cancer Institute","ror":"https://ror.org/0060x3y55","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I102322142","https://openalex.org/I4390039302","https://openalex.org/I4390039325"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"G\u00e9rard Greig","raw_affiliation_strings":["Cancer Therapy & Research Ctr., San Antonio, TX, Cancer Institute of New Jersey, New Brunswick, NJ, Hoffman-La Roche Inc., Nutley, NJ, MD Anderson Cancer Ctr, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Therapy & Research Ctr., San Antonio, TX, Cancer Institute of New Jersey, New Brunswick, NJ, Hoffman-La Roche Inc., Nutley, NJ, MD Anderson Cancer Ctr, Houston, TX","institution_ids":["https://openalex.org/I4390039325"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110122469","display_name":"Stanley Frankel","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4390039325","display_name":"Rutgers Cancer Institute","ror":"https://ror.org/0060x3y55","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I102322142","https://openalex.org/I4390039302","https://openalex.org/I4390039325"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Stanley Frankel","raw_affiliation_strings":["Cancer Therapy & Research Ctr., San Antonio, TX, Cancer Institute of New Jersey, New Brunswick, NJ, Hoffman-La Roche Inc., Nutley, NJ, MD Anderson Cancer Ctr, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Therapy & Research Ctr., San Antonio, TX, Cancer Institute of New Jersey, New Brunswick, NJ, Hoffman-La Roche Inc., Nutley, NJ, MD Anderson Cancer Ctr, Houston, TX","institution_ids":["https://openalex.org/I4390039325"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5053481267","display_name":"Razelle Kurzrock","orcid":"https://orcid.org/0000-0003-4110-1214","observed_orcids":["https://orcid.org/0000-0003-4110-1214"]},"institutions":[{"id":"https://openalex.org/I4390039325","display_name":"Rutgers Cancer Institute","ror":"https://ror.org/0060x3y55","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I102322142","https://openalex.org/I4390039302","https://openalex.org/I4390039325"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Razelle Kurzrock","raw_affiliation_strings":["Cancer Therapy & Research Ctr., San Antonio, TX, Cancer Institute of New Jersey, New Brunswick, NJ, Hoffman-La Roche Inc., Nutley, NJ, MD Anderson Cancer Ctr, Houston, TX"],"raw_orcid":"https://orcid.org/0000-0003-4110-1214","affiliations":[{"raw_affiliation_string":"Cancer Therapy & Research Ctr., San Antonio, TX, Cancer Institute of New Jersey, New Brunswick, NJ, Hoffman-La Roche Inc., Nutley, NJ, MD Anderson Cancer Ctr, Houston, TX","institution_ids":["https://openalex.org/I4390039325"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5033814974","display_name":"Eric Rubin","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4390039325","display_name":"Rutgers Cancer Institute","ror":"https://ror.org/0060x3y55","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I102322142","https://openalex.org/I4390039302","https://openalex.org/I4390039325"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Eric Rubin","raw_affiliation_strings":["Cancer Therapy & Research Ctr., San Antonio, TX, Cancer Institute of New Jersey, New Brunswick, NJ, Hoffman-La Roche Inc., Nutley, NJ, MD Anderson Cancer Ctr, Houston, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Cancer Therapy & Research Ctr., San Antonio, TX, Cancer Institute of New Jersey, New Brunswick, NJ, Hoffman-La Roche Inc., Nutley, NJ, MD Anderson Cancer Ctr, Houston, TX","institution_ids":["https://openalex.org/I4390039325"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I4390039325"],"apc_list":null,"apc_paid":null,"fwci":1.709,"has_fulltext":false,"cited_by_count":10,"citation_normalized_percentile":{"value":0.85562865,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":94},"biblio":{"volume":"6","issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10748","display_name":"Growth Hormone and Insulin-like Growth Factors","score":0.9955999851226807,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10748","display_name":"Growth Hormone and Insulin-like Growth Factors","score":0.9955999851226807,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11016","display_name":"Monoclonal and Polyclonal Antibodies Research","score":0.0008999999845400453,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/insulin-like-growth-factor-receptor","display_name":"insulin-like growth factor receptor","score":0.875},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.8420000076293945},{"id":"https://openalex.org/keywords/advanced-solid-tumors","display_name":"advanced solid tumors","score":0.8769999742507935},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.9100000262260437},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.9089999794960022},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9660000205039978},{"id":"https://openalex.org/keywords/tyrosine-kinase-inhibitors","display_name":"tyrosine kinase inhibitors","score":0.7179999947547913},{"id":"https://openalex.org/keywords/prostate-cancer","display_name":"prostate cancer","score":0.5329999923706055},{"id":"https://openalex.org/keywords/colon-cancer","display_name":"colon cancer","score":0.5820000171661377},{"id":"https://openalex.org/keywords/rectal-cancer","display_name":"rectal cancer","score":0.7540000081062317},{"id":"https://openalex.org/keywords/mesothelioma","display_name":"mesothelioma","score":0.8299999833106995},{"id":"https://openalex.org/keywords/head-and-neck-cancer","display_name":"head and neck cancer","score":0.6819999814033508},{"id":"https://openalex.org/keywords/uterine-leiomyosarcoma","display_name":"uterine leiomyosarcoma","score":0.8960000276565552}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7253952622413635},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.6179821491241455},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.5639521479606628},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.5548346638679504},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4824829399585724},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.46733081340789795},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4425426125526428},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4201250970363617}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2264947172","doi":null,"is_oa":false,"landing_page_url":"http://mct.aacrjournals.org/content/6/11_Supplement/A77","pdf_url":null,"source":{"id":"https://openalex.org/S48437117","display_name":"Molecular Cancer Therapeutics","issn_l":"1535-7163","issn":["1535-7163","1538-8514"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"Molecular Cancer Therapeutics","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2532022854","https://openalex.org/W2512096769","https://openalex.org/W2050416697","https://openalex.org/W2156136395","https://openalex.org/W2734688671","https://openalex.org/W1976269797","https://openalex.org/W1993624360","https://openalex.org/W2155000185","https://openalex.org/W2590559378","https://openalex.org/W2207381344"],"abstract_inverted_index":{"A77":[0],"Background:":[2],"Insulin-like":[3],"growth":[4],"factor":[5],"receptor":[6,14],"(IGF-1R)":[7],"is":[8,30,473],"a":[9,31,83,419],"tyrosine":[10],"kinase":[11],"cell":[12],"surface":[13],"frequently":[15],"activated":[16],"in":[17,56,62,191,317,343,355,364,380,413,455,506],"cancer":[18],"cells":[19,173],"which":[20,38],"mediates":[21],"the":[22,47,91,356,365,381,392,403,476,498,502],"mitogenic":[23],"and":[24,44,70,108,121,160,209,245,249,280,294,306,329,399,407,428,488],"anti-apoptotic":[25],"actions":[26],"of":[27,49,79,93,193,282,319,377,383,425,430,478],"IGF.":[28],"R1507":[29,50,472],"fully":[32],"human":[33],"anti-IGF-1R":[34],"monoclonal":[35],"antibody":[36],"(IgG1)":[37],"selectively":[39],"inhibits":[40],"IGF-1R.":[41],"The":[42],"safety":[43],"pharmacokinetics":[45],"(PK)":[46],"administration":[48],"every":[51,87,181],"3":[52,88,130,145,201,302],"weeks,":[53],"were":[54,75,153,188,273,341],"explored":[55],"this":[57],"phase":[58],"I":[59],"dose-escalation":[60],"study":[61,264],"patients":[63,186,321],"with":[64,257,471],"advanced":[65],"malignant":[66],"solid":[67],"tumors.":[68],"Materials":[69],"Methods:":[71],"Different":[72],"patient":[73],"cohorts":[74],"treated":[76],"withincreasing":[77],"doses":[78,492],"R1507,":[80],"administered":[81],"as":[82,127,497],"1":[84,192,197,252,255,277,357,447],"hour":[85],"infusion":[86],"weeks":[89,158,236],"until":[90],"development":[92],"dose-limiting":[94],"toxicity":[95,132,135,147],"(DLT)":[96],"or":[97,136,142,278],"progressive":[98],"disease.":[99],"Inclusion":[100],"criteria:":[101,115],"ECOG":[102],"PS":[103],"0-1,":[104],"adequate":[105],"hematologic,":[106],"hepatic,":[107],"renal":[109],"function,":[110],"CD4":[111,292,307],"count":[112],">200/\u00b5l.":[113],"Exclusion":[114],"infection,":[116],"immunosuppressive":[117],"agents,":[118],"diabetes":[119],"mellitus,":[120],"uncontrolled":[122],"intercurrent":[123],"illnesses.":[124],"DLT":[125,326],"defined":[126],">":[128,139,143,148,338],"grade":[129,140,144,276,301,339],"non-hematologic":[131],"(except":[133],"cardiac":[134],"hypersensitivity":[137],"reaction,":[138],"2),":[141],"hematologic":[146],"7":[149,467],"days.":[150,375],"PK:blood":[151],"samples":[152],"collected":[154],"following":[155],"dosing":[156],"on":[157,169,263,458,462],"1-4":[159],"7-10":[161],"for":[162,265,402],"non":[163],"compartmental":[164],"analysis.":[165],"Pharmacodynamics":[166],"(PD):":[167],"IGF-1R":[168,456],"peripheral":[170],"blood":[171],"mononuclear":[172],"(PBMC)":[174],"was":[175,179,327,332,379,395,460],"measured.":[176],"Response":[177],"(RECIST)":[178],"assessed":[180],"6":[182],"weeks.":[183,267],"Results:":[184],"26":[185],"(pts)":[187],"sequentially":[189],"enrolled":[190],"4":[194,372],"dose":[195,416,477],"levels:":[196],"mg/kg":[198,202,206,211,358,367,409,448,480],"(n=":[199,203,207,212],"7),":[200],"6),":[204],"9":[205,406],"6)":[208],"16":[210,366,408,479],"7).":[213],"Median":[214],"pt":[215,256],"age":[216],"59":[217],"yrs":[218],"(range":[219,453],"30-81),":[220],"M:F":[221],"16:10,":[222],"mean":[223],"prior":[224],"treatments":[225],"4.6":[226],"(range:":[227],"1-9).":[228],"Eleven":[229],"pts":[230,299],"showed":[231],"stable":[232],"disease,":[233],"median":[234,393],"20":[235,320],"[prostate":[237],"3,":[238,405],"colon":[239],"2;":[240],"rectum,":[241],"pleura":[242],"(mesothelioma),":[243],"head":[244],"neck,":[246],"uterus":[247],"(leiomyosarcoma),":[248],"cervix":[250],"-":[251,385],"each],":[253],"including":[254],"pancreatic":[258],"tumor":[259],"(neuroendocrine)":[260],"who":[261],"remains":[262],"55+":[266],"Safety:":[268],"Drug-related":[269],"adverse":[270],"events":[271],"(AEs)":[272],"mostly":[274],"(CTCAE)":[275],"2":[279,340],"consisted":[281],"fatigue":[283],"(5":[284],"pts);":[285],"diarrhea":[286],"(3);":[287],"anorexia,":[288],"rash,":[289],"weight":[290],"loss,":[291],"reduction,":[293],"dyspepsia":[295],"(2":[296],"each).":[297],"Two":[298],"had":[300],"drug-related":[303,336],"AEs:":[304],"hyperglycemia":[305],"reduction.":[308],"Glucose":[309],"tolerance":[310],"test":[311],"changed":[312],"from":[313,351,371],"negative":[314],"to":[315,360,373,439],"positive":[316],"5":[318],"at":[322,475],"week":[323,390],"7.":[324],"No":[325,335],"reported":[328,342],"an":[330,449],"MTD":[331],"not":[333,494],"reached.":[334],"AE":[337],"15":[344],"(57%)":[345],"pts.":[346],"PK:":[347],"Clearance":[348,426],"(CL)":[349,427],"decreased":[350],"812":[352],"mL/Day":[353,362],"(CV=36.8%)":[354],"group":[359],"437":[361],"(CV=40.9%)":[363],"group.":[368],"T1/2":[369],"increased":[370],"11":[374],"Volume":[376,429],"distribution":[378,431],"range":[382],"4.4":[384],"5.0":[386],"L":[387],"(CV=16.0-34.8%).":[388],"At":[389,446],"10,":[391],"Css,min":[394],"1.1,":[396],"12.7,":[397],"31.0,":[398],"102.0":[400],"ug/mL":[401],"1,":[404],"groups":[410],"respectively.":[411],"Decrease":[412],"CL":[414],"across":[415],"levels":[417],"suggests":[418],"saturable":[420],"elimination":[421],"pathway.":[422],"Mean":[423],"values":[424],"(Vd)":[432],"calculated":[433,441],"after":[434,442],"multiple":[435],"administrations":[436],"remained":[437],"comparable":[438],"those":[440],"single":[443],"administration.":[444],"PD:":[445],"average":[450],"80%":[451],"reduction":[452],"13-34%)":[454],"expression":[457],"PBMC":[459],"seen":[461],"day":[463],"8":[464],"(n":[465],"=":[466],"pts).":[468],"Conclusions:":[469],"Treatment":[470],"tolerable":[474],"q3W":[481],"without":[482],"DLT.":[483],"Treatment-related":[484],"toxicities":[485],"are":[486,493],"mild":[487],"clinically":[489],"manageable.":[490],"Higher":[491],"being":[495],"tested":[496],"trough":[499],"concentration":[500],"meets":[501],"target":[503],"level":[504],"identified":[505],"preclinical":[507],"xenograft":[508],"models.":[509]},"counts_by_year":[{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-17T09:40:24.721904","created_date":"2016-06-24T00:00:00"}